We are a biotechnology company focused on the discovery and development of
lipidomic-based therapeutic antibodies, an emerging field of medical science
that targets bioactive signaling lipids to treat a wide range of human diseases.
We have two product candidates that are currently in clinical development, and
one in pre-clinical evaluation.
iSONEP� is the ocular formulation of sonepcizumab, a humanized monoclonal
antibody (�mAb�) against sphingosine-1-phosphate (�S1P�). Sphingomab� is the
original mouse version of this monoclonal antibody. iSONEP is administered by
intravitreal injection, and has demonstrated multiple mechanisms of action in
ocular models of disease, including anti-angiogenesis, anti-inflammatory,
anti-fibrotic and anti-vascular permeability.